Genitourinary Cancer

The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence.

Radical prostatectomy was not associated with significantly lower all-cause or prostate-cancer mortality than observation.

FDA approval was given to a new regimen of cabazitaxel (Jevtana) to treat men with metastatic castration-resistant prostate cancer who previously received a docetaxel-containing regimen. The approval is for 20 mg/m2 every 3 weeks in combination with prednisone. The agency approved a dose of 25 mg/m2 every 3 weeks in this patient population in 2010.

Patients with untreated advanced renal cell carcinoma (RCC) lived significantly longer without disease progression when they received the multikinase inhibitor cabozantinib (Cabometyx) as initial therapy versus sunitinib (Sutent), according to results of an independent review of the randomized CABOSUN trial reported at the 2017 ESMO Congress in Madrid.

The FDA announced today that it has approved the first biosimilar for the treatment of multiple types of cancer.

Updated United States Preventive Services Task Force (USPSTF) guidelines on prostate cancer screening were recently published in Cancer.

A patient can experience less pain, a quicker healing time and potentially more normal kidney function, due to the minimally invasive aspect of robotic surgery, according to Ketan K. Badani, M.D.

Bladder cancer is uncommon, and is more often diagnosed at an advanced stage because it has symptoms that mimic other disorders.

For years, people believed that there was a link between vasectomies and prostate cancer.

The risk of developing certain types of cancer can be increased by exposure to work-related stress.

Researchers found that the rate of suicide in patients with lung cancer is much higher than those with other types of cancer.

A recent study looked at the long-term health-related effects of treatment for patients with localized prostate cancer, finding that some can continue for more than 10 years after treatment.

The incidence of prostate cancer is 60% in black men in the US than in white men, and they are twice as likely to die from the disease.

According to findings presented at the 2017 ASCO Annual Meeting, earlier intervention with abiraterone acetate (Zytiga) lowered the risk of death by 40% for men with high-risk advanced or metastatic prostate cancer.

The Bladder Cancer Advocacy Network (BCAN) announced the recipients of the 2017 Young Investigator Awards.

A recent study provides more evidence toward the link between electronic cigarette use and bladder cancer risk.

More Stage I cancers were diagnosed after the passage of the Affordable Care Act (ACA), also known as Obamacare, within five screenable disease types: colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer).

The FDA has granted approval to pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

The FDA has granted accelerated approval to avelumab (Bavencio) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

ASCO has updated their guidance on the use of second-line hormonal therapy for chemotherapy-naive patients with castration-resistant prostrate cancer (CRPC).

The FDA has granted accelerated approval for the PD-L1 inhibitor durvalumab for the treatment of locally advanced or metastatic urothelial carcinoma.

The Food and Drug Administration (FDA) granted an accelerated approval to atezolizumab (Tecentriq) to be used as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma (mUC).

There may be a shift away from the USPSTF's opposition to routine PSA screening for prostate cancer in some men.

A recent review has found substantial evidence linking androgen deprivation therapy (ADT) to dementia in patients with prostate cancer.

With antiretroviral drugs easing the burden of AIDS-defining cancers in HIV-positive patients, the most common cancers in this population are expected to shift to those associated with aging.